IP Law News

Novartis Notches Patent Wins on MS, Cancer, Transplant Drugs (1)

Dec. 7, 2018, 4:02 PMUpdated: Dec. 7, 2018, 10:05 PM

Novartis AG scored big wins in two separate patent cases at a federal appeals court—one involving a patent on the multiple sclerosis drug Gilenya and the other on a patent related to the cancer and transplant-related drugs Zortress and Afinitor.

Both cases involve the complex interplay between the determination whether a patent’s claims are obvious and, therefore, invalid, and patent term extensions. How a court works out these issues can mean life or death for a drug patent—and can affect when cheaper, generic versions of blockbuster drugs enter the market.

In the Gilenya case, Ezra Ventures sought to sell...

To read the full article log in. To learn more about a subscription click here.